(Q33364775)
Statements
1 reference
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial (English)
1 reference
Neil Senzer
1 reference
James Arsenau
1 reference
Donald Richards
1 reference
Barry Berman
1 reference
John R MacDonald
1 reference
Sheri Smith
1 reference
1 February 2005
1 reference
1 reference
28
1 reference
36-42
1 reference
Identifiers
1 reference
1 reference